Matthew Galsky on Treating Different Subsets of Bladder Cancer
Matthew Galsky, MD, medical oncologist, Icahn School of Medicine at Mount Sinai, discusses treating different subsets of bladder cancer.
Matthew Galsky, MD, medical oncologist, Icahn School of Medicine at Mount Sinai, discusses treating different subsets of bladder cancer.
The most common type of bladder cancer, non muscle invasive, is highly curable with standard treatment. Cure still remains a possibility as the cancer spreads to the muscle later, though there is an increased chance of further spread. Then as the cancer spreads to regional lymph nodes and then becomes distant metastatic disease, the potential for cure decreases, but Galsky is hopeful that the developments of new targets will offer more options to these patients.
Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes vs Chemo in Urothelial Cancer
April 20th 2024Patients with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin plus pembrolizumab experienced a reduction in the risk for disease progression or death vs chemotherapy.
Maintenance Avelumab Has Similar Efficacy in Real World for Urothelial Cancer
March 5th 2024Patients with metastatic urothelial cancer treated with frontline maintenance therapy with avelumab following platinum-based chemotherapy in the real-world setting had similar outcomes as observed in the JAVELIN Bladder 100 trial.
Key Advances in Cancer Survivorship Toxicity Management
July 15th 2022In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.
